Literature DB >> 17236606

Medical care and alcohol use after testing hepatitis C antibody positive at STD clinic and HIV test site screening programs.

Karen E Mark1, Paula J Murray, David B Callahan, Robert A Gunn.   

Abstract

OBJECTIVES: The Centers for Disease Control and Prevention recommend screening individuals at risk for hepatitis C virus (HCV) infection. However, few published data describe outcomes of individuals with antibody to HCV (anti-HCV) identified through screening programs. The purpose of this study was to assess rates of medical evaluation and HCV treatment, change in alcohol consumption, and barriers to medical care after testing anti-HCV positive through a public screening program.
METHODS: Anti-HCV positive individuals identified through San Diego sexually transmitted disease (STD) clinics and an HIV test site screening program were informed of positive test results, provided education and referral, and contacted by telephone three, six, and > or =12 months later.
RESULTS: From September 1, 1999, to December 31, 2001, 411 anti-HCV positive individuals were newly identified, of whom 286 (70%) could be contacted > or = three months after receipt of test results (median length [range] of follow-up 14 [3-35] months). Of these 286, 156 (55%) reported having received a medical evaluation, of whom 19 (12%) began HCV treatment. Of 132 who reported drinking alcohol before diagnosis, 100 (76%) reported drinking less after diagnosis. Individuals with medical insurance at diagnosis were more likely than those without insurance to obtain a medical evaluation during follow-up (75 [68%] of 111 vs. 70 [45%] of 155; p < 0.001). Among those who did not obtain an evaluation, the most commonly reported reason was lack of insurance.
CONCLUSIONS: Only about half of newly identified anti-HCV positive individuals received a medical evaluation, although 76% reported drinking less alcohol. Identifying ways to improve medical access for those who are anti-HCV positive could improve the effectiveness of screening programs.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17236606      PMCID: PMC1802122          DOI: 10.1177/003335490712200105

Source DB:  PubMed          Journal:  Public Health Rep        ISSN: 0033-3549            Impact factor:   2.792


  18 in total

Review 1.  National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002--June 10-12, 2002.

Authors: 
Journal:  Hepatology       Date:  2002-11       Impact factor: 17.425

2.  The prevalence of hepatitis C virus infection in the United States, 1988 through 1994.

Authors:  M J Alter; D Kruszon-Moran; O V Nainan; G M McQuillan; F Gao; L A Moyer; R A Kaslow; H S Margolis
Journal:  N Engl J Med       Date:  1999-08-19       Impact factor: 91.245

Review 3.  Hepatitis C virus infection in the United States.

Authors:  M J Alter
Journal:  J Hepatol       Date:  1999       Impact factor: 25.083

4.  Chronic hepatitis C in Latinos: natural history, treatment eligibility, acceptance, and outcomes.

Authors:  Ramsey C Cheung; Sue Currie; Hui Shen; Samuel B Ho; Edmund J Bini; Bhupinderjit S Anand; Norbert Bräu; Teresa L Wright
Journal:  Am J Gastroenterol       Date:  2005-10       Impact factor: 10.864

5.  Treating hepatitis C virus infection in active substance users.

Authors:  Diana L Sylvestre
Journal:  Clin Infect Dis       Date:  2005-04-15       Impact factor: 9.079

6.  Integrating services for injection drug users infected with hepatitis C virus with methadone maintenance treatment: challenges and opportunities.

Authors:  Alain H Litwin; Irene Soloway; Marc N Gourevitch
Journal:  Clin Infect Dis       Date:  2005-04-15       Impact factor: 9.079

Review 7.  Treatment for hepatitis C virus infection among current injection drug users in Australia.

Authors:  Gail Matthews; Ian J Kronborg; Gregory J Dore
Journal:  Clin Infect Dis       Date:  2005-04-15       Impact factor: 9.079

8.  Treatment of chronic hepatitis C in injecting drug users: 5 years' follow-up.

Authors:  O Dalgard; K Bjøro; K Hellum; B Myrvang; K Skaug; B Gutigard; H Bell
Journal:  Eur Addict Res       Date:  2002-01       Impact factor: 3.015

9.  Effect of case management on unmet needs and utilization of medical care and medications among HIV-infected persons.

Authors:  M H Katz; W E Cunningham; J A Fleishman; R M Andersen; T Kellogg; S A Bozzette; M F Shapiro
Journal:  Ann Intern Med       Date:  2001-10-16       Impact factor: 25.391

10.  Treating hepatitis C in methadone maintenance patients: an interim analysis.

Authors:  Diana L Sylvestre
Journal:  Drug Alcohol Depend       Date:  2002-07-01       Impact factor: 4.492

View more
  9 in total

1.  Integrating viral hepatitis prevention into public health programs serving people at high risk for infection: good public health.

Authors:  Joanna Buffington; T Stephen Jones
Journal:  Public Health Rep       Date:  2007       Impact factor: 2.792

Review 2.  Hepatitis infection in the treatment of opioid dependence and abuse.

Authors:  Thomas F Kresina; Diana Sylvestre; Leonard Seeff; Alain H Litwin; Kenneth Hoffman; Robert Lubran; H Westley Clark
Journal:  Subst Abuse       Date:  2008-04-28

3.  HIV, Hepatitis C, and Abstinence from Alcohol Among Injection and Non-injection Drug Users.

Authors:  Jennifer C Elliott; Deborah S Hasin; Malka Stohl; Don C Des Jarlais
Journal:  AIDS Behav       Date:  2016-03

4.  Low prevalence of hepatitis C virus antibody in men who have sex with men who do not inject drugs.

Authors:  Joanna Buffington; Paula J Murray; Karen Schlanger; Linda Shih; Tracy Badsgard; Robin R Hennessy; Robert Wood; Isaac B Weisfuse; Robert A Gunn
Journal:  Public Health Rep       Date:  2007       Impact factor: 2.792

5.  Cost-effectiveness of rapid hepatitis C virus (HCV) testing and simultaneous rapid HCV and HIV testing in substance abuse treatment programs.

Authors:  Bruce R Schackman; Jared A Leff; Devra M Barter; Madeline A DiLorenzo; Daniel J Feaster; Lisa R Metsch; Kenneth A Freedberg; Benjamin P Linas
Journal:  Addiction       Date:  2015-01       Impact factor: 7.256

6.  The hepatitis C cascade of care: identifying priorities to improve clinical outcomes.

Authors:  Benjamin P Linas; Devra M Barter; Jared A Leff; Sabrina A Assoumou; Joshua A Salomon; Milton C Weinstein; Arthur Y Kim; Bruce R Schackman
Journal:  PLoS One       Date:  2014-05-19       Impact factor: 3.752

7.  Cocaine Use and Liver Disease are Associated with All-Cause Mortality in the Miami Adult Studies in HIV (MASH) Cohort.

Authors:  Adriana Campa; Sabrina Sales Martinez; Kenneth E Sherman; Joe Pedro Greer; Yinghui Li; Stephanie Garcia; Tiffanie Stewart; Boubakari Ibrahimou; O Dale Williams; Marianna K Baum
Journal:  J Drug Abuse       Date:  2016-11-07

8.  Cost-Effectiveness of One-Time Hepatitis C Screening Strategies Among Adolescents and Young Adults in Primary Care Settings.

Authors:  Sabrina A Assoumou; Abriana Tasillo; Jared A Leff; Bruce R Schackman; Mari-Lynn Drainoni; C Robert Horsburgh; M Anita Barry; Craig Regis; Arthur Y Kim; Alison Marshall; Sheel Saxena; Peter C Smith; Benjamin P Linas
Journal:  Clin Infect Dis       Date:  2018-01-18       Impact factor: 20.999

9.  A descriptive analysis of concurrent alcohol and substance use among patients living with HIV/HCV co-infection.

Authors:  Omar T Sims; Kaiying Wang; Rasheeta Chandler; Pamela A Melton; Duong N Truong
Journal:  Soc Work Health Care       Date:  2020-09-02
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.